fluorobenzenes has been researched along with Body Weight in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T | 1 |
| Li, WH; Ma, YX; Xie, Q | 1 |
| Dorajoo, Rs; Gopalakrishnakone, P; Lee, E; Leong, CC; Pereira, BP; Wee, A; Yu, Z | 1 |
| Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W | 1 |
| Dai, G; Ma, P; Pei, Y; Wang, X; Xu, Q; Yan, L; Zhang, W; Zhang, X; Zheng, P | 1 |
| Arai, H; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Gierman, LM; Huizinga, TW; Kleemann, R; Kloppenburg, M; Kooistra, T; Koudijs, A; Stojanovic-Susulic, V; Stoop, R; van der Ham, F; van Osch, GJ; Wielinga, PY; Zuurmond, AM | 1 |
| Adamkova, V; Kralova Lesna, I; Pagacova, L | 1 |
| Chai, HT; Chang, HW; Chang, LT; Chen, YT; Chung, SY; Ko, SF; Leu, S; Lin, KC; Sun, CK; Yen, CH; Yip, HK | 1 |
| Abo-Gresha, NM; Zaitone, SA | 1 |
| Tuomilehto, J | 1 |
| Bleske, BE; Boluyt, MO; Cirrincione, GM; Hwang, HS | 1 |
| Cooper, SA; Ferrario, C; Habibi, J; Hayden, MR; Muniyappa, R; Qazi, MA; Sowers, JR; Stump, C; Thyfault, J; Tramontano, A; Whaley-Connell, A | 1 |
| Balligand, JL; Davey, PC; De Keyzer, D; Desjardins, F; Geeraert, B; Herregods, MC; Holvoet, P; Mertens, A; Smith, G; Verreth, W | 1 |
| Cooper, SA; DeMarco, VG; Hayden, MR; Lastra, G; Manrique, C; Nistala, R; Sowers, JR; Wei, Y; Westerly, B; Whaley-Connell, A; Wiedmeyer, C | 1 |
| Ku, DD; Sun, X | 1 |
| Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA | 1 |
| Al-Shamma, H; Behan, D; Chalmers, D; Chen, W; Espitia, S; Grottick, AJ; Martin, M; Menzaghi, F; Morgan, M; Reyes-Saldana, H; Smith, B; Thomsen, WJ; Whelan, K; Yuskin, D | 1 |
| Bigley, A; Marsden, AM; Randall, K; Scott, RC; Westwood, FR | 1 |
| Dekanski, JB | 1 |
| Chaouloff, F; Kulikov, A; Mormède, P | 1 |
| Hixson, CJ; Kinkead, ER; Kutzman, RS; Tice, RR; Vinegar, A; Wall, HG | 1 |
1 review(s) available for fluorobenzenes and Body Weight
| Article | Year |
|---|---|
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Fluorobenzenes; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Metformin; Motor Activity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
1 trial(s) available for fluorobenzenes and Body Weight
| Article | Year |
|---|---|
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fatty Liver; Female; Fluorobenzenes; Glucose Clamp Technique; Glyburide; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Intra-Abdominal Fat; Italy; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Subcutaneous Fat; Sulfonamides; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography | 2013 |
20 other study(ies) available for fluorobenzenes and Body Weight
| Article | Year |
|---|---|
Rosuvastatin inhibits TGF-beta1 expression and alleviates myocardial fibrosis in diabetic rats.
Topics: Animals; Body Weight; Cardiomyopathies; Collagen; Creatine Kinase; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Fluorobenzenes; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Pyrimidines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1 | 2013 |
Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy.
Topics: Animals; Body Weight; Electron Transport Complex IV; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron, Transmission; Mitochondria, Muscle; Multidrug Resistance-Associated Proteins; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Paraffin Embedding; Probenecid; Pyrimidines; Rats; Rats, Sprague-Dawley; Renal Agents; Rosuvastatin Calcium; Sulfonamides | 2008 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholesterol, Dietary; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Mice; Mice, Knockout; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Body Weight; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Organ Size; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Ventricular Dysfunction, Right | 2011 |
Differential effect of statins on diabetic nephropathy in db/db mice.
Topics: Adiposity; Albuminuria; Animals; Blood Pressure; Body Weight; Creatinine; Diabetic Nephropathies; Fluorobenzenes; Insulin Resistance; Male; Mice; Oxidative Stress; Pravastatin; Pyrimidines; Quinolines; Real-Time Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2011 |
Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice.
Topics: Animals; Body Weight; C-Reactive Protein; Cytokines; Diet, High-Fat; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inflammation; Insulin; Male; Mice; Mice, Transgenic; Obesity; Osteoarthritis; Pyrimidines; Rosiglitazone; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2012 |
Effect of rosuvastatin treatment on cholesterol efflux from human macrophages.
Topics: Aged; Biological Transport; Body Weight; Cell Line, Tumor; Cells, Cultured; Cholesterol; Cholesterol, HDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Macrophages; Male; Middle Aged; Pilot Projects; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Waist Circumference | 2011 |
Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: role of signaling pathways and therapeutic impact of rosuvastatin.
Topics: Adenine; Animals; Biomarkers; Blood Urea Nitrogen; Body Weight; Creatinine; Cytoprotection; Disease Models, Animal; Endothelial Cells; Environmental Pollutants; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phenols; Protein Kinase C; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors | 2012 |
Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF.
Topics: Acute Disease; Animals; Body Weight; Electrocardiography; Fluorobenzenes; Heart Ventricles; Isoproterenol; Male; Myocardial Infarction; Neovascularization, Physiologic; Nitric Oxide Synthase Type II; Organ Size; Pyrimidines; Rats; Rats, Wistar; Receptors, Complement 3b; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Blotting, Western; Body Weight; Cardiomegaly; Collagen; Constriction, Pathologic; DNA Probes; Extracellular Matrix; Fibronectins; Fluorobenzenes; Gene Expression; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Organ Size; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling | 2006 |
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
Topics: Animals; Animals, Genetically Modified; Biomarkers; Blood Pressure; Body Weight; Cardiomegaly; Coronary Vessels; Female; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Mice; Myocardium; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Pyrimidines; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Renin; Rosuvastatin Calcium; Sulfonamides; Ventricular Remodeling | 2007 |
Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
Topics: Animals; Aorta; Atherosclerosis; Blood Glucose; Body Weight; Cell Line; Dyslipidemias; Fluorobenzenes; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Leptin; Lipids; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; PPAR gamma; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase | 2007 |
Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Fluorobenzenes; Glomerular Filtration Rate; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Microscopy, Electron, Transmission; Obesity; Oxidative Stress; Podocytes; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase | 2008 |
Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats.
Topics: Animals; Blood Pressure; Blotting, Western; Body Weight; Coronary Disease; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide; Organ Size; Poisons; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2008 |
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Diabetes Mellitus, Type 2; Enalapril; Endothelium, Vascular; Fatty Acids; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Metabolic Syndrome; Oxidative Stress; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Topics: Aminopyridines; Animals; Behavior, Animal; Benzazepines; Body Weight; Brain; Cell Line; Dopamine; Eating; Fluorobenzenes; Humans; Indoles; Male; Norepinephrine; Obesity; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Recombinant Proteins; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 2008 |
Rosuvastatin: characterization of induced myopathy in the rat.
Topics: Administration, Oral; Animals; Biomarkers; Body Weight; Creatine Kinase; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Muscular Diseases; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Anti-prostatic activity of bifluranol, a fluorinated bibenzyl.
Topics: Androgen Antagonists; Animals; Antispermatogenic Agents; Body Weight; Castration; Estrogens, Non-Steroidal; Fertility; Fluorobenzenes; Gonadotropins; Hexestrol; Male; Mice; Prostate; Rats; Sexual Behavior, Animal; Testosterone Congeners | 1980 |
Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Body Weight; Cerebral Cortex; Female; Fluorobenzenes; Ketanserin; Male; Maze Learning; Phenols; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1997 |
Chloropentafluorobenzene: short-term inhalation toxicity, genotoxicity and physiologically-based pharmacokinetic model development.
Topics: Administration, Inhalation; Animals; Body Weight; Bone Marrow; Dose-Response Relationship, Drug; Erythrocytes; Female; Fluorobenzenes; Male; Mice; Mice, Inbred Strains; Micronuclei, Chromosome-Defective; Models, Biological; Organ Size; Rats; Rats, Inbred F344; Sister Chromatid Exchange; Tissue Distribution | 1990 |